PDF(Pubmed)
Abstract：
UNASSIGNED: Atypical chronic myeloid leukemia (aCML) is a BCR::ABL1 negative myelodysplastic/myeloproliferative neoplasm with poor overall survival. Some patients can be treated by allogeneic hematopoietic stem cell transplantation (allo-HSCT) from suitable donors. The effectiveness of decitabine or azacitidine (AZA) has recently been reported; however, their combined efficacy with selinexor has not yet been reported.
UNASSIGNED: In this study, we report the case of a patient with aCML who was successfully treated with selinexor combined with AZA. A 67-year-old man with a history of gastric mucosa-associated lymphoid tissue (MALT) lymphoma was admitted to the hospital with fatigue and emaciation. He was diagnosed with aCML and no longer responded to decitabine treatment after undergoing seven cycles. The patient was subsequently administered hydroxyurea (HU), selinexor, and AZA. After four courses of combination therapy, his blood cell counts improved; he no longer required transfusions and was able to discontinue HU. The patient continued receiving selinexor and AZA without severe complications. This case is the first to show that combinatorial selinexor and AZA therapy can effectively treat aCML.
UNASSIGNED: Our case sheds light on the importance of selinexor and AZA combined therapy in the exploration of new treatment strategies for aCML. Moreover, this treatment approach offers the possibility of bridging with allo-HSCT.
UNASSIGNED: In this study, we report the case of a patient with aCML who was successfully treated with selinexor combined with AZA. A 67-year-old man with a history of gastric mucosa-associated lymphoid tissue (MALT) lymphoma was admitted to the hospital with fatigue and emaciation. He was diagnosed with aCML and no longer responded to decitabine treatment after undergoing seven cycles. The patient was subsequently administered hydroxyurea (HU), selinexor, and AZA. After four courses of combination therapy, his blood cell counts improved; he no longer required transfusions and was able to discontinue HU. The patient continued receiving selinexor and AZA without severe complications. This case is the first to show that combinatorial selinexor and AZA therapy can effectively treat aCML.
UNASSIGNED: Our case sheds light on the importance of selinexor and AZA combined therapy in the exploration of new treatment strategies for aCML. Moreover, this treatment approach offers the possibility of bridging with allo-HSCT.
摘要：
■非典型慢性粒细胞白血病（aCML）是一种BCR::ABL1阴性骨髓增生异常/骨髓增殖性肿瘤，总体生存率较差。一些患者可以通过来自合适供体的同种异体造血干细胞移植(allo-HSCT)来治疗。最近报道了地西他滨或阿扎胞苷（AZA）的有效性；然而，它们与selinexor的联合疗效尚未报道。
■在这项研究中，我们报告了一例aCML患者成功接受selinexor联合AZA治疗.一名67岁的有胃粘膜相关淋巴组织（MALT）淋巴瘤病史的男子因疲劳和消瘦而入院。他被诊断为aCML，在经历了七个周期后，对地西他滨治疗不再有反应。患者随后服用羟基脲（HU），selinexor,还有AZA.经过四个疗程的联合治疗，他的血细胞计数有所改善;他不再需要输血，并且能够停止HU。患者继续接受selinexor和AZA治疗，无严重并发症。该病例首次表明selinexor和AZA联合治疗可有效治疗aCML。
■我们的案例揭示了selinexor和AZA联合治疗在探索aCML新治疗策略中的重要性。此外，这种治疗方法提供了与allo-HSCT桥接的可能性.
■在这项研究中，我们报告了一例aCML患者成功接受selinexor联合AZA治疗.一名67岁的有胃粘膜相关淋巴组织（MALT）淋巴瘤病史的男子因疲劳和消瘦而入院。他被诊断为aCML，在经历了七个周期后，对地西他滨治疗不再有反应。患者随后服用羟基脲（HU），selinexor,还有AZA.经过四个疗程的联合治疗，他的血细胞计数有所改善;他不再需要输血，并且能够停止HU。患者继续接受selinexor和AZA治疗，无严重并发症。该病例首次表明selinexor和AZA联合治疗可有效治疗aCML。
■我们的案例揭示了selinexor和AZA联合治疗在探索aCML新治疗策略中的重要性。此外，这种治疗方法提供了与allo-HSCT桥接的可能性.
